LABOPHARM INC. (incorporated under Part IA of the Companies Act (Québec)) 11,000,000 Common Shares PURCHASE AGREEMENTPurchase Agreement • April 28th, 2006 • Labopharm Inc • Pharmaceutical preparations • New York
As United States regulatory counsel to the Company, we are familiar with the United States Federal Food, Drug, and Cosmetic Act (the “FDC Act”) and the regulations promulgated thereunder and matters as applied generally to drugs of the nature under development and clinical testing by the Company and have reviewed the Registration Statement, the U.S. Prospectus and the Canadian Prospectus, including the documents incorporated by reference therein, particularly the portions thereof under the captions “Risk Factors — Risks Related to Our Business — We depend heavily on the success of our lead product candidate, our once-daily tramadol, and if the new drug application, or NDA, for our once-daily tramadol is not approved on a timely basis or at all, it would have a material adverse effect on our business, financial condition and results of operations,” “Risk Factors — Risks Related to Our Business — If we fail to obtain regulatory approvals for our product candidates under development, we w
CONFIDENTIAL LICENSE AGREEMENT Between LABOPHARM EUROPE LIMITED ANGELINI LABOPHARM LP May 20, 2010License Agreement • June 11th, 2010 • Labopharm Inc • Pharmaceutical preparations • England and Wales
In conformity with paragraph 12.2 (3) of National Instrument 51-102 respecting Continuous Disclosure Obligations, Labopharm Inc. has redacted certain provisions of this agreement. Redacted provisions relate to payment terms and other confidential commercial terms.
AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF LABOPHARM PHARMACEUTICALS, LLC - among – LABOPHARM PHARMACEUTICALS, LLC - and - LABOPHARM USA, INC. - and - ANGELINI PHARMACEUTICALS, INC. May 20, 2010Limited Liability Company Agreement • June 11th, 2010 • Labopharm Inc • Pharmaceutical preparations • Delaware
AMONG: LABOPHARM PHARMACEUTICALS, LLC, a limited liability company incorporated pursuant to the laws of Delaware with its principal office at 202 Carnegie Center, Suite 204 Princeton, NJ 08540, United States;
LIMITED PARTNERSHIP AGREEMENT - among - LABOPHARM EUROPE LIMITED - and - AMUCHINA S.p.A. - and - ANGELINI LABOPHARM MGP LIMITED - and - ANGELINI LABOPHARM SGP LIMITED May 20, 2010Limited Partnership Agreement • June 11th, 2010 • Labopharm Inc • Pharmaceutical preparations
AMONG: LABOPHARM EUROPE LIMITED, a company incorporated pursuant to the laws of the Republic of Ireland with its registered office at Unit 5 Seapoint Building, 44-45 Clontarf Road, Dublin 3, Ireland;
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 31st, 2011 • Labopharm Inc • Pharmaceutical preparations • New York
This Second Amendment, dated as of December 31, 2010 (this "Second Amendment"), to the Exclusive License Agreement dated as of August 12, 2005, as amended by the First Amendment to Exclusive License Agreement dated as of October 31, 2005 (as amended, the "Agreement"), is between Labopharm Europe Limited, an Irish corporation having its place of business at 5 The Seapoint Building, 45 Clontarf Road, Dublin 3, Ireland ("LEL"), and Purdue Pharma Products L.P., a Delaware limited partnership having its place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901 USA ("Purdue").
